FHIR IG analytics

Resources that use this resource

No resources found

Resources that this resource uses

No resources found

Narrative

Note: links and images are rebased to the (stated) source

Source1

{
  "resourceType": "CodeSystem",
  "id": "scd-blood-product-processing-cs",
  "text": {
    "status": "generated",
    "div": "<!-- snip (see above) -->"
  },
  "url": "http://hl7.org/fhir/us/uscdi-scd/CodeSystem/scd-blood-product-processing-cs",
  "version": "0.1.0",
  "name": "SCDBloodProductProcessingCS",
  "title": "SCD Blood Product Processing Code System",
  "status": "active",
  "experimental": false,
  "date": "2026-09-11T00:10:30+00:00",
  "publisher": "HL7 International / Public Health",
  "contact": [
    {
      "name": "HL7 International / Public Health",
      "telecom": [
        {
          "system": "url",
          "value": "https://www.hl7.org/Special/committees/pher"
        },
        {
          "system": "email",
          "value": "pher@lists.HL7.org"
        }
      ]
    },
    {
      "name": "HL7 Public Health Work Group",
      "telecom": [
        {
          "system": "url",
          "value": "http://www.hl7.org/Special/committees/pher"
        },
        {
          "system": "email",
          "value": "pher@lists.HL7.org"
        }
      ]
    }
  ],
  "description": "Local code system for blood product processing steps and attributes\nrelevant to transfusion therapy in Sickle Cell Disease. Covers extended\nantigen matching criteria, processing modifiers, and product selection\nrequirements specific to SCD care.\n\nTODO: Map to ISBT 128 processing codes and SNOMED CT where equivalents\nexist. Consider ISBT 128 as the primary coding system and use this only\nfor concepts not yet covered.",
  "jurisdiction": [
    {
      "coding": [
        {
          "system": "urn:iso:std:iso:3166",
          "code": "US",
          "display": "United States of America"
        }
      ]
    }
  ],
  "caseSensitive": true,
  "content": "complete",
  "count": 11,
  "concept": [
    {
      "code": "leukoreduced",
      "display": "Leukoreduced",
      "definition": "Blood product from which the majority of leukocytes have been removed\n     by filtration (leukoreduction). Standard of care for SCD patients to\n     reduce febrile non-hemolytic transfusion reactions, CMV transmission\n     risk, and HLA alloimmunization."
    },
    {
      "code": "irradiated",
      "display": "Irradiated",
      "definition": "Blood product that has been exposed to gamma radiation or X-ray irradiation\n     to inactivate T-lymphocytes, preventing transfusion-associated graft-vs-host\n     disease (TA-GvHD). Required for immunocompromised SCD patients and those\n     post-HSCT."
    },
    {
      "code": "cmv-negative",
      "display": "CMV Seronegative",
      "definition": "Blood product collected from a donor who tested negative for cytomegalovirus\n     (CMV) antibodies. Required for CMV-seronegative immunocompromised patients."
    },
    {
      "code": "sickle-cell-negative",
      "display": "Sickle Cell Trait Negative (HbS Negative)",
      "definition": "Blood product confirmed to be from a donor who does not carry the sickle\n     hemoglobin trait (HbAS) or disease (HbSS). Required for exchange transfusion\n     in SCD patients to ensure post-transfusion HbS reduction is effective."
    },
    {
      "code": "antigen-matched-C-neg",
      "display": "C Antigen Negative (Rh system)",
      "definition": "Blood product confirmed negative for the C antigen (Rh2) in the Rhesus\n     blood group system. Used in antigen-matched transfusion for SCD patients\n     who are C antigen negative."
    },
    {
      "code": "antigen-matched-E-neg",
      "display": "E Antigen Negative (Rh system)",
      "definition": "Blood product confirmed negative for the E antigen (Rh3) in the Rhesus\n     blood group system. Used in antigen-matched transfusion for SCD patients\n     who are E antigen negative."
    },
    {
      "code": "antigen-matched-K-neg",
      "display": "K Antigen Negative (Kell system)",
      "definition": "Blood product confirmed negative for the K antigen (KEL1) in the Kell\n     blood group system. Used in antigen-matched transfusion for SCD patients\n     who are K antigen negative (the majority of Black donors are K-negative)."
    },
    {
      "code": "antigen-matched-Fya-neg",
      "display": "Fya Antigen Negative (Duffy system)",
      "definition": "Blood product confirmed negative for the Fya antigen (FY1) in the Duffy\n     blood group system. Used in antigen-matched transfusion for SCD patients\n     who are Fya antigen negative."
    },
    {
      "code": "antigen-matched-Jkb-neg",
      "display": "Jkb Antigen Negative (Kidd system)",
      "definition": "Blood product confirmed negative for the Jkb antigen (JK2) in the Kidd\n     blood group system. Used in antigen-matched transfusion for SCD patients\n     who are Jkb antigen negative."
    },
    {
      "code": "extended-phenotype-matched",
      "display": "Extended Phenotype Matched",
      "definition": "Blood product matched for an extended panel of red cell antigens beyond\n     ABO/Rh D, typically including C, E, K, Fya, and Jkb at minimum,\n     per the prescribing institution's SCD transfusion protocol."
    },
    {
      "code": "fresh-blood",
      "display": "Fresh Blood (≤7 days)",
      "definition": "Blood product collected within 7 days of planned transfusion date.\n     Preferred for automated red cell exchange in SCD to optimize post-exchange\n     HbS% reduction and 2,3-DPG levels."
    }
  ]
}